Healthcare Industry News: sanofi-aventis
News Release - March 20, 2006
Abraxis Oncology Names Joseph Hogan Vice President of U.S. Sales and MarketingSCHAUMBURG, Ill.--(HSMN NewsFeed)--March 20, 2006--American BioScience Inc. and American Pharmaceutical Partners, Inc. (NASDAQ:APPX ) today announced the appointment of Joseph Hogan to the new position of vice president of U.S. sales and marketing for Abraxis(TM) Oncology. Hogan will be responsible for leading the U.S. sales and marketing teams for ABRAXANEŽ for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and will be reporting to Barry Flannelly, Pharm.D, global vice president of sales and marketing. At the close of the merger between American Pharmaceutical Partners (APP) and American BioScience (ABI) in the second quarter of this year, Abraxis Oncology will become a division of Abraxis BioScience, a fully integrated global biopharmaceutical company.
"We are fortunate to have Joe join the Abraxis Oncology team. His experience and deep understanding of the needs of cancer patients will be invaluable as we work toward transforming the way cancer is treated," said Flannelly. "Joe will play a critical role in the expansion of our U.S. sales and marketing activities that will help physicians and patients to better understand the benefits of next generation cancer therapies."
Mr. Hogan brings to Abraxis Oncology extensive expertise in sales, marketing and global brand development in the oncology field. Hogan was most recently head of global oncology marketing for Berlex. Prior to joining Berlex, he served in numerous leadership positions at sanofi-aventis, including that of U.S. marketing director for TaxotereŽ where he played a key role in developing brand strategy for the product in breast, lung and prostate cancers.
About American BioScience, Inc.
American BioScience, Inc. is a privately held biotechnology company focused on the discovery, development and delivery of next-generation therapeutics including biologically active molecules already existing within the human biological system, for the treatment of life-threatening diseases. ABI owns a majority interest in American Pharmaceutical Partners, Inc.
About American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. Abraxis(TM) Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANEŽ for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). For more information, visit APP's website at www.appdrugs.com and www.abraxisoncology.com.
TaxotereŽ is a registered trademark of Aventis Pharmaceuticals, Inc.
Source: American Pharmaceutical Partners
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.